| Literature DB >> 24384537 |
Maria Grazia Pascucci1, Valentina Di Gregori2, Gabriella Frasca1, Paola Rucci2, Alba Carola Finarelli1, Laura Moschella1, Bianca Maria Borrini1, Francesca Cavrini3, Giovanna Liguori3, Vittorio Sambri4, Paolo Bonanni5, Maria Pia Fantini2.
Abstract
The incidence of reported meningococcal disease in Italy is among the lowest in Europe. The trend of the disease was increasing up to 2005 and then declined after the gradual introduction of a universal Men C vaccination program in 17/21 Italian regions. Since 2006, in Emilia-Romagna region vaccination against Neisseria meningitidis serogroup C was actively offered free of charge in a single dose to the age groups 12-15 months and 14-15 years, in addition to people with defined epidemiological risk. Our aim was to measure the impact of vaccination on the incidence of meningococcal disease caused by different serogroups among the population of Emilia Romagna Region, Northern Italy (approximately 4.5 million inhabitants) subdivided by age. Using surveillance data, we computed the incidence rates of Neisseria meninigitidis related invasive disease per 100.000 inhabitants for the years 2000 to 2012. In addition, the percentage change in incidence and the mortality rates were calculated. Results indicate a 70.1% decrease in the incidence of meningococcus C-related invasive disease after the introduction of MenC universal vaccination. No case of serogroup C related infection was observed since 2006 in children aged 1-4 years. These findings suggest that the single-dose vaccination strategy against serogroup C N.meningitidis targeted to the age groups 12-15 months and 14-15 years was effective in the Emilia-Romagna population. However, the occurrence of two cases of meningiditis in a 5-month child and in a 9-years child suggests caution and careful consideration in surveillance for the next years.Entities:
Keywords: meningococcal disease; serogroups; surveillance; vaccination campaign; vaccination coverage; vaccination strategies
Mesh:
Substances:
Year: 2013 PMID: 24384537 PMCID: PMC4130270 DOI: 10.4161/hv.27597
Source DB: PubMed Journal: Hum Vaccin Immunother ISSN: 2164-5515 Impact factor: 3.452